Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services



Gallus BioPharmaceuticals, a St. Louis-based CMO has acquired Laureate Biopharmaceutical Services, a biologics CMO located in Princeton, New Jersey. This acquisition doubles Gallus’ process development and clinical drug-substance-manufacturing capacity and adds full protein characterization, testing, and clinical fill-finish capability. With the acquisition, Gallus has two centers of excellence. The Princeton site is a Center of Excellence for process development and manufacture of clinical-stage products, including fill-finish, and the St. Louis site is a Center of Excellence for process development and clinical and commercial manufacture of biopharmaceutical products.

Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.

Source: Gallus BioPharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here